Answer to the question:
No. In the AugustâŻ11âŻpress release announcing the upcoming Q2âŻ2025 earnings call, ProPhase Labs did not disclose any updated revenue or earnings guidance for the remainder of 2025. The announcement was limited to the scheduling of the virtual conference call; there was no mention of revised forwardâlooking numbers, revised forecasts, or guidance revisions.
Trading implications:
Because the company has not supplied updated guidance, the marketâs pricing of PRPH will remain anchored to the consensus consensusâderived expectations from prior quarters and the broader biotech sector sentiment. Until the AugustâŻ13 earnings release, investors should rely on the existing consensus outlook for 2025 (which, at this point, reflects the companyâs 2024â2025 guidance published earlier in the year). In the shortâterm, the stock is likely to trade within the technical range established after the last earnings beat; traders can watch the 50âday and 200âday movingâaverage alignment for clues on momentum. If the forthcoming earnings call contains a surprise â either a raised outlook or a downârevision â the stock could experience a sharp move, so positioning with a tight stopâloss or using options (e.g., a straddle/strangle around the earnings release) would be prudent. In the meantime, maintain a neutral stance until the earnings call reveals any guidance change.